SSGJ-627 / 3SBio - LARVOL DELTA

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC (clinicaltrials.gov) - P2 | N=288 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC (clinicaltrials.gov) - P2 | N=288 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Evaluation of 627 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=108 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P1 trial

Sunshine Guojian's Class 1 antibody new drug was approved for clinical trials for ulcerative colitis [Google translation] (Sina Corp) - "Today (April 3), the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that the Class 1 new drug SSGJ-627 injection applied by Sunshine Guojian(27.360, -1.64, -5.66%) was approved for clinical trials and is intended to be developed to treat ulcerative colitis (UC)....This is the first time that this product has been approved for clinical trials in China."

New trial • Ulcerative Colitis